longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Edwards Lifesciences

EW

85.1901.31% ( -1.130 )
Closed: Oct 1, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 48.86, above the reasonable range, cheaper than 6.38% of the time in the past 3 years, and the industry ranks 39/174, the industry Median -0.89.

48.86xP/E
$85.19Stock price
$1.74Earnings per share
48.86xP/E
Stock price$85.19Earnings per share$1.74

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
31.96x
Typical range
10.64x–42.00x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
ISRGUSIntuitive Surgical
45.16x17.25%$141.75B
EWUSEdwards Lifesciences
48.86x38.29%$49.10B
BDXUSBecton Dickinson and
51.49x10.84%$48.50B
CHEOYUSCochlear Limited
59.50x--$5.92B
IRMDUSiRadimed
47.31x10.67%$1.09B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.